Lantern Pharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
LTRN$0.46-22.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – December 31, 2025 and 2024
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $4,422,838 | $7,511,079 |
| Marketable securities | 5,696,386 | 16,501,984 |
| Prepaid expenses & other current assets | 683,948 | 1,234,566 |
| Total current assets | 10,803,172 | 25,247,629 |
| Property and equipment, net | 31,875 | 47,440 |
| Operating lease right-of-use assets | 75,595 | 239,985 |
| Deferred offering costs | 88,431 | - |
| Other assets | 36,738 | 36,738 |
| TOTAL ASSETS | $11,035,811 | $25,571,792 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $4,423,048 | $4,140,361 |
| Operating lease liabilities, current | 78,539 | 190,814 |
| Total current liabilities | 4,501,587 | 4,331,175 |
| Operating lease liabilities, net of current portion | - | 52,843 |
| TOTAL LIABILITIES | 4,501,587 | 4,384,018 |
| COMMITMENTS AND CONTINGENCIES (NOTE 4) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Preferred Stock (1,000,000 authorized at December 31, 2025 and December 31, 2024; $.0001 par value) (Zero shares issued and outstanding at December 31, 2025 and December 31, 2024) | - | - |
| Common Stock (25,000,000 authorized at December 31, 2025 and December 31, 2024; $.0001 par value) (11,254,697 shares issued and outstanding at December 31, 2025; 10,784,725 shares issued and outstanding at December 31, 2024) | 1,125 | 1,078 |
| Additional paid-in capital | 99,652,724 | 97,058,323 |
| Accumulated other comprehensive income | 25,430 | 153,990 |
| Accumulated deficit | (93,145,055) | (76,025,617) |
| Total stockholders’ equity | 6,534,224 | 21,187,774 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $11,035,811 | $25,571,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.